Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Immtech Conducts Joint US/China Trials for Pneumonia Drug

publication date: Nov 30, 2007

Immtech Pharmaceuticals has enlisted Jubo Liu, PhD, to serve as Development Liaison for Clinical Trials in China. Currently, Immtech is conducting a Phase III trial of pafuramidine as a treatment for pneumocystis pneumonia (PCP), a fungal infections affecting patients with compromised immune systems. This includes people with HIV/AIDS and transplant patients. An estimated 1 million people worldwide suffer from the disease, while another 5 million people are treated prophylactically for the disease. The China State Food & Drug Administration recently granted Fast Track Status to the Phase III trial of pafuramidine. More details...

Stock Symbols: (AMEX: IMM) (NYSE: PRX) (NSDQ: VRTX)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here